Mustang Bio Past Earnings Performance
Past criteria checks 0/6
Mustang Bio's earnings have been declining at an average annual rate of -3.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 103.7% per year.
Key information
-3.5%
Earnings growth rate
26.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 103.7% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Mustang Bio: This Horse May Gallop Still
Sep 23Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?
Aug 09
Mustang Bio: The Market Is Missing This Opportunity
May 03Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?
Dec 29Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Sep 14Mustang Bio (MBIO) EHA Investor Presentations - Slideshow
Jun 18Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Jun 11Checking Back In On Mustang Bio
May 26FDA accepts Mustang Bio's MB-106 application in cancer
May 10Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
Mar 22What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?
Feb 23Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price
Jan 28
Revenue & Expenses Breakdown
How Mustang Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -32 | 7 | 24 |
| 31 Mar 24 | 0 | -40 | 9 | 31 |
| 31 Dec 23 | 0 | -52 | 10 | 41 |
| 30 Sep 23 | 0 | -63 | 10 | 51 |
| 30 Jun 23 | 0 | -72 | 11 | 57 |
| 31 Mar 23 | 0 | -74 | 11 | 62 |
| 31 Dec 22 | 0 | -78 | 12 | 64 |
| 30 Sep 22 | 0 | -78 | 12 | 64 |
| 30 Jun 22 | 0 | -76 | 11 | 64 |
| 31 Mar 22 | 0 | -71 | 11 | 60 |
| 31 Dec 21 | 0 | -66 | 11 | 56 |
| 30 Sep 21 | 0 | -67 | 11 | 57 |
| 30 Jun 21 | 0 | -63 | 11 | 50 |
| 31 Mar 21 | 0 | -63 | 11 | 49 |
| 31 Dec 20 | 0 | -60 | 10 | 47 |
| 30 Sep 20 | 0 | -56 | 9 | 43 |
| 30 Jun 20 | 0 | -53 | 9 | 43 |
| 31 Mar 20 | 0 | -49 | 9 | 38 |
| 31 Dec 19 | 0 | -46 | 10 | 36 |
| 30 Sep 19 | 0 | -42 | 10 | 32 |
| 30 Jun 19 | 0 | -39 | 9 | 30 |
| 31 Mar 19 | 0 | -34 | 8 | 27 |
| 31 Dec 18 | 0 | -31 | 7 | 24 |
| 30 Sep 18 | 0 | -34 | 6 | 27 |
| 30 Jun 18 | 0 | -34 | 9 | 23 |
| 31 Mar 18 | 0 | -34 | 9 | 23 |
| 31 Dec 17 | 0 | -31 | 9 | 20 |
| 30 Sep 17 | 0 | -24 | 9 | 15 |
| 30 Jun 17 | 0 | -19 | 6 | 13 |
| 31 Mar 17 | 0 | -15 | 5 | 9 |
| 31 Dec 16 | 0 | -13 | 3 | 9 |
| 30 Sep 16 | 0 | -6 | 2 | 3 |
| 30 Jun 16 | 0 | -5 | 1 | 3 |
| 31 Mar 16 | 0 | -4 | 1 | 3 |
Quality Earnings: MBIO is currently unprofitable.
Growing Profit Margin: MBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MBIO is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare MBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: MBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.